CN101780124A - Capparis acutifolia sweet exact and preparation method and application thereof - Google Patents
Capparis acutifolia sweet exact and preparation method and application thereof Download PDFInfo
- Publication number
- CN101780124A CN101780124A CN201010122485A CN201010122485A CN101780124A CN 101780124 A CN101780124 A CN 101780124A CN 201010122485 A CN201010122485 A CN 201010122485A CN 201010122485 A CN201010122485 A CN 201010122485A CN 101780124 A CN101780124 A CN 101780124A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- pain
- thousand miles
- lone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 241001406863 Capparis acutifolia Species 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 62
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 31
- 238000000605 extraction Methods 0.000 claims abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 238000010992 reflux Methods 0.000 claims abstract description 16
- 208000002193 Pain Diseases 0.000 claims abstract description 14
- 230000036407 pain Effects 0.000 claims abstract description 14
- 239000000287 crude extract Substances 0.000 claims abstract description 7
- 208000004998 Abdominal Pain Diseases 0.000 claims abstract description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 claims abstract description 4
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 4
- 206010058019 Cancer Pain Diseases 0.000 claims abstract description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 3
- 208000004296 neuralgia Diseases 0.000 claims abstract description 3
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 3
- 208000004371 toothache Diseases 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 6
- 239000003435 antirheumatic agent Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 1
- 229940124583 pain medication Drugs 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 208000009386 Experimental Arthritis Diseases 0.000 abstract description 8
- 230000000202 analgesic effect Effects 0.000 abstract description 6
- 208000034656 Contusions Diseases 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 241000700159 Rattus Species 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000008961 swelling Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000008096 xylene Substances 0.000 description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940097766 aspirin 200 mg Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 230000001760 anti-analgesic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000873224 Capparaceae Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000009395 Zhengqing Fengtongning Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000002036 chloroform fraction Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 201000010603 frozen shoulder Diseases 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CGFYHILWFSGVJS-UHFFFAOYSA-N silicic acid;trioxotungsten Chemical class O[Si](O)(O)O.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1.O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 CGFYHILWFSGVJS-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 240000007700 Caltha palustris var. membranacea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001530038 Pantherophis obsoletus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- XWTXZJITNNRDLC-UHFFFAOYSA-K bis[(2-hydroxyacetyl)oxy]alumanyl 2-hydroxyacetate Chemical compound [Al+3].OCC([O-])=O.OCC([O-])=O.OCC([O-])=O XWTXZJITNNRDLC-UHFFFAOYSA-K 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229940043266 rosin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种独行千里提取物及其制备方法和应用。所述独行千里提取物是取植物独行千里根茎,粉碎后加热回流、冷浸或渗漏提取,减压浓缩得到粗提浸膏,用氯仿提取粗提浸膏得到,可应用于制备治疗神经病理性疼痛、治疗炎性疼痛、治疗癌症性疼痛、治疗糖尿病疼痛、治疗风湿病疼痛、治疗跌打损伤疼痛、治疗咽喉肿痛、治疗牙痛或治疗腹痛药物方面,具有很好的镇痛、抗炎活性,对弗氏完全佐剂性关节炎效果明显。本发明的制备工艺具有成本低、易于工业化生产的特点。
The invention discloses an extract of a thousand miles alone and its preparation method and application. The extract of the plant is taken from the rhizome of the plant, crushed, heated to reflux, cold soaked or leaked for extraction, concentrated under reduced pressure to obtain a crude extract, which is obtained by extracting the crude extract with chloroform, which can be applied to the preparation of neuropathic neuropathic Pain, treatment of inflammatory pain, treatment of cancer pain, treatment of diabetes pain, treatment of rheumatism pain, treatment of pain from bruises, treatment of sore throat, treatment of toothache or treatment of abdominal pain drugs, has good analgesic and anti-inflammatory activities , It has obvious effect on Freund's complete adjuvant arthritis. The preparation process of the invention has the characteristics of low cost and easy industrial production.
Description
技术领域technical field
本发明属于医药技术领域,具体涉及一种独行千里提取物及其制备方法和其在制备抗炎镇痛、抗风湿性关节炎药物方面的应用。The invention belongs to the technical field of medicines, and in particular relates to an extract of a thousand miles alone, its preparation method and its application in the preparation of anti-inflammatory, analgesic and anti-rheumatic arthritis drugs.
背景技术Background technique
独行千里为山柑科(Capparaceae)植物独行千里Capparisacutifolia Sweet〔C.membranacea Gardn.et Champ.〕的干燥根。别名扣钮子(广东乳源)、膜叶槌果藤、独虎龙、黑皮蛇、黑钩榕(海南)等,产于广东、广西、江西(大余)、福建(沙县、崇安、延平)、湖南(宜章)、台湾;生于低海拔灌丛、林中、旷野或山坡路旁。本品为我国南方的民间草药。性平,味苦、涩,有毒;功能活血散瘀,解痉止痛。用于治疗风湿关节痛,筋骨不舒,咽喉肿痛,腹痛;外用根或叶治疮疖肿毒,跌打损伤。It is the dry root of Capparisacutifolia Sweet [C.membranacea Gardn.et Champ.], a plant of Capparaceae (Capparaceae). Alias button button (Guangdong milk source), membranous leaf mallet fruit vine, Duhulong, black snake, black hook banyan (Hainan), etc., produced in Guangdong, Guangxi, Jiangxi (Dayu), Fujian (Shaxian, Chong'an) , Yanping), Hunan (Yizhang), Taiwan; born in low-altitude shrubs, forests, wilderness or hillside roadsides. This product is a folk herbal medicine in southern my country. Flat in nature, bitter in the mouth, astringent, poisonous; Function promoting blood circulation and dispelling blood stasis, relieving spasm and relieving pain. It is used to treat rheumatic arthralgia, muscle and bone discomfort, sore throat, and abdominal pain; the root or leaves are used externally to treat sores, furuncles, swollen toxins, and traumatic injuries.
目前独行千里在临床上应用多为简单加工使用,可以内服或外用;粗提制剂,成分复杂,普遍存在着粗、大、黑的不足,因其有效部位的不明确,临床应用存在服用剂量较难控制和治疗效果不稳定等缺陷。亟需在药效学引导下,筛选独行千里的有效部位并加以应用研究,但目前尚无独行千里有效部位提取工艺、最佳提取条件的报道,也未见其提取物在抗炎镇痛、抗炎抗风湿药理方面的研究报道。At present, the clinical application of Lonely Thousand Miles is mostly simple processing and use, which can be taken orally or externally; crude extraction preparations have complex components, and generally have the shortcomings of being thick, large, and black. Defects such as difficult control and unstable therapeutic effect. Under the guidance of pharmacodynamics, it is urgent to screen the effective parts of Lonely Thousand Miles and carry out applied research. However, there is no report on the extraction process and optimal extraction conditions of the effective parts of Lonely Thousand Miles. Research reports on anti-inflammatory and anti-rheumatic pharmacology.
发明内容Contents of the invention
本发明的目的是克服现有技术的不足,提供一种独行千里提取物。The purpose of the present invention is to overcome the deficiencies in the prior art and provide a kind of extract of a thousand miles alone.
本发明的另一个目的是提供所述提取物的制备方法。Another object of the present invention is to provide a preparation method of the extract.
本发明还有一个目的是提供所述独行千里提取物的应用。Another object of the present invention is to provide the application of the extract of the thousand miles alone.
本发明的目的通过下述技术方案予以实现:The purpose of the present invention is achieved through the following technical solutions:
提供一种独行千里提取物,是取植物独行千里根茎,粉碎后加热回流、冷浸或渗漏提取,减压浓缩得到粗提浸膏,用氯仿提取得到。Provided is an extract of the solitary plant, which is obtained by taking the rhizome of the plant climax, pulverizing it, heating to reflux, cold soaking or seepage extraction, concentrating under reduced pressure to obtain a crude extract, and extracting it with chloroform.
本发明提供了所述独行千里提取物的制备方法,包括以下步骤:The present invention provides the preparation method of described Alone Thousand Miles extract, comprises the following steps:
(1)独行千里根茎干燥后粉碎成粗粉;(1) Dried rhizomes of Duxingqianli are crushed into coarse powder;
(2)采用体积比浓度为70~95%的乙醇浸提、回流提取或超声提取独行千里根茎粉;合并提取液,减压浓缩得浸膏;(2) using ethanol extraction, reflux extraction or ultrasonic extraction with a volume ratio concentration of 70% to 95% of the rhizome powder of the Rhizome of Lone Flower; combine the extracts and concentrate under reduced pressure to obtain the extract;
或采用体积比浓度为70~95%的乙醇渗漏提取独行千里根茎粉;合并提取液,减压浓缩得浸膏;Or use ethanol with a volume ratio concentration of 70% to 95% to leak and extract the rhizome powder of Duxingqianli; combine the extracts, concentrate under reduced pressure to obtain the extract;
(3)将步骤(2)所得浸膏经柱层析纯化后,即得独行千里有效部位:氯仿部位或乙酸乙酯部位;(3) After the extract obtained in step (2) is purified by column chromatography, the effective part of the independent journey can be obtained: the chloroform part or the ethyl acetate part;
或将步骤(3)所得浸膏经石油醚脱脂后以氯仿萃取、氯仿回流提取或氯仿超声提取,提取液减压回收氯仿,得稠膏,即为独行千里有效部位。Alternatively, the extract obtained in step (3) is degreased with petroleum ether, extracted with chloroform, refluxed with chloroform or ultrasonically extracted with chloroform, and the extract is decompressed to recover chloroform to obtain a thick paste, which is the effective part of a thousand miles alone.
步骤(2)若采用乙醇浸提,乙醇的加入量优选按照独行千里根茎粉重量的8~20倍量加入;优选浸提3次,每次1天~7天;Step (2) If ethanol extraction is used, the amount of ethanol is preferably added according to 8 to 20 times the weight of the rhizome powder of Lone Walking Thousand Miles; it is preferably extracted 3 times, each time for 1 to 7 days;
步骤(2)若采用乙醇回流提取,乙醇的加入量优选按照独行千里根茎粉重量的8~20倍量加入;优选提取2~3次,每次1~6小时;Step (2) If ethanol is used for reflux extraction, the amount of ethanol is preferably added according to 8 to 20 times the weight of the rhizome powder of Lone Walking Thousand Miles; it is preferably extracted 2 to 3 times, each time for 1 to 6 hours;
或步骤(2)所述乙醇超声提取,乙醇的加入量优选按照独行千里根茎粉重量的8~20倍量加入,超声提取2~3次,每次1~6小时;Or the ethanol ultrasonic extraction described in step (2), the addition of ethanol is preferably added according to 8 to 20 times the weight of the rhizome powder of Lone Walking Thousand Miles, and the ultrasonic extraction is 2 to 3 times, 1 to 6 hours each time;
或步骤(2)所述乙醇渗漏提取,优选流速1~3ml/秒,直至渗漏液颜色较淡为止。Or the ethanol seepage extraction described in step (2), preferably at a flow rate of 1 to 3 ml/sec, until the seepage is lighter in color.
本发明还同时提供了另一独行千里提取物的制备方法,包括以下步骤:The present invention also simultaneously provides another preparation method of the extract of a thousand miles alone, comprising the following steps:
(A)独行千里根茎干燥后粉碎成粗粉;(A) the rhizome of Duxingqianli is dried and pulverized into coarse powder;
(B)采用60~80%乙醇回流提取独行千里根茎粉,合并提取液,减压浓缩得浸膏;(B) using 60-80% ethanol to reflux to extract the rhizome powder of Lonely Thousand Miles, combine the extracts, concentrate under reduced pressure to obtain the extract;
(C)以1~2%(体积比浓度)的稀酸水(可采用盐酸或硫酸等)酸化后(优选酸化至PH值为2~3),酸水液以氨水调PH值至9~11,氯仿萃取,减压回收氯仿所得稠膏,即为独行千里有效部位。(C) After acidifying (preferably acidifying to a pH value of 2 to 3) with 1 to 2% (volume ratio concentration) of dilute acid water (hydrochloric acid or sulfuric acid, etc.), the acid water liquid is adjusted to a pH value of 9 to 9 with ammonia water. 11. Chloroform extraction, the thick paste obtained by recovering chloroform under reduced pressure is the effective part of Lone Walking Thousand Miles.
步骤(B)乙醇的加入量是独行千里根茎粗粉重量的8~20倍,提取3次,每次1~6小时。The amount of ethanol added in step (B) is 8 to 20 times the weight of the rhizome powder of Lone Walking Thousand Miles, and the extraction is performed 3 times, each time for 1 to 6 hours.
本发明成功从植物独行千里中提取抗炎镇痛、抗关节炎有效部位将原料粉碎后加热回流、冷浸或渗漏提取,减压浓缩得到粗提浸膏,依次用石油醚、氯仿、乙酸乙酯、正丁醇、丙酮、水等提取,得到不同部位,进行药理粗筛,本发明将氯仿部位进行进行碘化汞钾、碘化铋钾、硅钨酸生物碱指示剂的试管定性反应,均呈阳性反应,说明本发明制备得到的独行千里有效部位为总生物碱成分,经系统的抗炎镇痛及抗弗氏完全佐剂性关节炎实验,其抗炎、镇痛、抗佐剂性关节炎效果明显,证明其具有显著的药理作用,可用于制备抗炎镇痛、抗风湿性关节炎、类风湿性关节炎、痛风、肩周炎的药物,为临床用药提供新的选择。The present invention successfully extracts anti-inflammatory, analgesic and anti-arthritic effective parts from the plant. The raw material is pulverized and then heated to reflux, cold soaked or leaked to extract, and concentrated under reduced pressure to obtain a crude extract, which is sequentially extracted with petroleum ether, chloroform, and acetic acid. Ethyl ester, n-butanol, acetone, water, etc. are extracted to obtain different parts and undergo pharmacological rough screening. In the present invention, the chloroform parts are subjected to qualitative reactions in test tubes of mercuric potassium iodide, bismuth potassium iodide, and silicotungstic acid alkaloid indicators. , all showed a positive reaction, indicating that the effective part of Duxingqianli prepared by the present invention is the total alkaloid component. After systematic anti-inflammatory and analgesic and anti-Freund's complete adjuvant arthritis experiments, its anti-inflammatory, analgesic, anti-adjuvant The effect of drug-induced arthritis is obvious, which proves that it has significant pharmacological effects, and can be used to prepare drugs for anti-inflammatory and analgesic, anti-rheumatic arthritis, rheumatoid arthritis, gout, and frozen shoulder, providing a new choice for clinical medication .
因此,本发明同时提供了独行千里提取物在制备治疗抗炎镇痛、抗风湿性关节炎、类风湿性关节炎、痛风、肩周炎药物方面的应用。Therefore, the present invention also provides the application of the extract of Duxingqianli in the preparation of anti-inflammatory and analgesic drugs, anti-rheumatic arthritis, rheumatoid arthritis, gout, and frozen shoulder.
优选地,所述独行千里提取物可应用于制备治疗神经病理性疼痛药物、治疗炎性疼痛药物、治疗癌症性疼痛药物、治疗糖尿病疼痛药物,可应用于制备治疗风湿病疼痛药物、跌打损伤疼痛、咽喉肿痛、牙痛、腹痛(特别是痉挛性疼痛)等药物。Preferably, the extract of the lone traveler can be applied to the preparation of medicines for treating neuropathic pain, medicine for treating inflammatory pain, medicine for treating cancer pain, medicine for treating pain in diabetes, medicine for treating rheumatism pain, pain from bruises, etc. , sore throat, toothache, abdominal pain (especially spasmodic pain) and other drugs.
上述应用,优选的剂量是0.5~200mg/kg体重。For the above application, the preferred dose is 0.5-200 mg/kg body weight.
所述有效部位可以加入药剂学允许的赋形剂制备成各种药物制剂,制剂形式有口服片剂、胶囊、丸剂、颗粒剂、散剂、口服液或乳剂;或者外用涂抹剂、膏剂、巴布剂、贴剂或凝胶剂。The effective part can be prepared into various pharmaceutical preparations by adding pharmaceutically acceptable excipients, and the preparation forms include oral tablets, capsules, pills, granules, powders, oral liquids or emulsions; or external lotions, ointments, cataplasms elixirs, patches or gels.
本发明的有益效果是:The beneficial effects of the present invention are:
本发明对独行千里原料药材中的有效成分进行了充分的提取、浓缩、分离,得到的有效部位(所述独行千里提取物)占药材重量的0.2~1.5%左右,具有显著的药理功效,可抗炎镇痛、抗风湿性关节炎。The present invention fully extracts, concentrates, and separates the effective components in the medicinal material of the lone thousand miles, and the obtained effective part (the extract of the lone thousand miles) accounts for about 0.2 to 1.5% of the weight of the medicinal material, has remarkable pharmacological effects, and can Anti-inflammatory analgesic, anti-rheumatoid arthritis.
本发明获得的有效部位优于粗提物入药,便于制成各种制剂,为临床用药提供新的选择。The effective part obtained by the present invention is better than the crude extract used as medicine, and is convenient to be made into various preparations, providing a new choice for clinical medicine.
本发明方法设计合理,具有工艺过程简单、成本低、能耗低的特点。The method of the invention is reasonable in design and has the characteristics of simple process, low cost and low energy consumption.
附图说明Description of drawings
图1模型组大鼠踝关节腔光镜结构图Figure 1 Structural diagram of the ankle joint of model group rats under endoscopic light microscope
图2独行千里有效部位大剂量组对大鼠踝关节腔光镜结构图Figure 2 Lone Travel Thousand Miles Effective Part High-dose Group on the structure diagram of rat ankle joint cavity light microscope
图3独行千里有效部位中剂量组对大鼠踝关节腔光镜结构图Figure 3 Lone Walking Thousand Miles effective part of the middle dose group on the rat ankle cavity light microscope structure diagram
图4独行千里有效部位小剂量组对大鼠踝关节腔光镜结构图Figure 4 Lone Travel Thousand Miles effective part small dose group on rat ankle cavity light microscope structure diagram
图5阳性对照组对大鼠踝关节腔光镜结构图Fig. 5 Positive control group to rat ankle arthroscopy structural diagram
具体实施方式Detailed ways
下面结合附图和具体实施例对本发明做进一步详细说明。通过大量实验总结得到本发明技术方案,总结见前述发明内容部分,乙醇浸提、回流提取、超声提取、渗漏提取中乙醇的加入量、浸提次数及时间等参数的优选方案不一一在实施例中赘述,但并不因此限定本发明范围。The present invention will be described in further detail below in conjunction with the accompanying drawings and specific embodiments. Through a large number of experiments, the technical solution of the present invention is obtained. For the summary, see the aforementioned content of the invention. The preferred schemes of the parameters such as the amount of ethanol added, the number of times of extraction and the time in the extraction of ethanol extraction, reflux extraction, ultrasonic extraction, and seepage extraction are different. The examples are described in detail, but do not limit the scope of the present invention.
实施例1独行千里有效部位(即独行千里提取物)的制备Embodiment 1 The preparation of the effective part of a thousand miles alone (i.e. the extract of a thousand miles alone)
取粉碎后的独行千里(根茎)2公斤左右,加12倍量(重量:体积)95%乙醇浸提7天,过滤后滤渣再用10倍量95%乙醇浸提5天,过滤后滤渣再用10倍量95%乙醇浸提3天,合并滤液,减压回收乙醇,得到浸膏。浸膏用60g硅胶拌匀后上硅胶柱,分别以石油醚、氯仿、乙酸乙酯、正丁醇、丙酮洗脱,减压回收溶剂,得到的氯仿部位、乙酸乙酯部位分别为5.8g和6.1g。Get about 2 kilograms of the crushed Lone Walking Thousand Miles (rhizome), add 12 times the amount (weight: volume) of 95% ethanol to extract for 7 days, filter the residue and then use 10 times the amount of 95% alcohol to extract it for 5 days, and filter the residue again Extract with 10 times the amount of 95% ethanol for 3 days, combine the filtrates, recover the ethanol under reduced pressure, and obtain the extract. The extract is mixed with 60g of silica gel and put on a silica gel column, eluting with petroleum ether, chloroform, ethyl acetate, n-butanol and acetone respectively, and recovering the solvent under reduced pressure, the obtained chloroform parts and ethyl acetate parts are respectively 5.8g and 6.1 g.
实施例2独行千里有效部位的制备Example 2 The preparation of the effective fraction of traveling thousands of miles alone
取粉碎独行千里(根茎)2公斤左右,加12倍量85%乙醇超声(100KHZ)3次,每次45min,得到浸膏约86.2g。浸膏用60g硅胶拌匀后,分别以石油醚、氯仿、乙酸乙酯、正丁醇、丙酮回流提取3次,每次10倍量溶剂,提取1小时;减压回收溶剂,得到的氯仿部位、乙酸乙酯部位分别为9.2g和10.9g。Take about 2 kg of crushed Lone Walking Thousand Miles (rhizome), add 12 times the amount of 85% ethanol and sonicate (100KHZ) 3 times, each time for 45 minutes, to obtain about 86.2 g of extract. After the extract was mixed well with 60g of silica gel, it was extracted 3 times with petroleum ether, chloroform, ethyl acetate, n-butanol, and acetone under reflux, each time with 10 times the amount of solvent, and extracted for 1 hour; the solvent was recovered under reduced pressure, and the obtained chloroform part , ethyl acetate parts were 9.2g and 10.9g.
实施例3独行千里有效部位的制备Example 3 The preparation of the effective part of traveling thousands of miles alone
取粉碎独行千里(根茎)2公斤左右,加12倍量85%乙醇回流提取3次,分别为2小时、1小时、1小时,得到浸膏约95.2g。浸膏用60g硅胶拌匀后,分别以石油醚、氯仿、乙酸乙酯、正丁醇、丙酮回流提取3次,每次10倍量溶剂,提取1小时;减压回收溶剂,得到的氯仿部位、乙酸乙酯部位分别为11.1g和12.6g。Take about 2 kilograms of crushed Lone Walker (rhizome), add 12 times the amount of 85% ethanol to reflux and extract 3 times, respectively for 2 hours, 1 hour, and 1 hour, to obtain about 95.2 g of extract. After the extract was mixed well with 60g of silica gel, it was extracted 3 times with petroleum ether, chloroform, ethyl acetate, n-butanol, and acetone under reflux, each time with 10 times the amount of solvent, and extracted for 1 hour; the solvent was recovered under reduced pressure, and the obtained chloroform part , ethyl acetate parts were 11.1g and 12.6g, respectively.
实施例4独行千里有效部位的制备Example 4 Preparation of effective fractions of traveling thousands of miles alone
取粉碎后的独行千里(根茎)2公斤左右,加95%乙醇渗漏提取,流速1~3ml/min,至提取液颜色较淡无生物碱显色反应,回收乙醇,得到浸膏约91.3g。石油醚脱脂后,用水混悬,再分别以氯仿、乙酸乙酯、正丁醇、丙酮萃取,得到的萃取液分别浓缩,得到氯仿部位和乙酸乙酯部位分别为6.3g和7.2g。Take about 2 kg of the crushed Lone Walking Thousand Miles (rhizome), add 95% ethanol to extract by leakage, the flow rate is 1-3ml/min, until the color of the extract is light and there is no alkaloid color reaction, recover the ethanol, and obtain about 91.3g of extract . After degreasing petroleum ether, suspend in water, then extract with chloroform, ethyl acetate, n-butanol, and acetone respectively, and concentrate the obtained extracts to obtain 6.3 g of chloroform fraction and 7.2 g of ethyl acetate fraction, respectively.
实施例5独行千里有效部位的制备Example 5 The preparation of the effective part of traveling thousands of miles alone
独行千里根茎干燥后粉碎,分别加入20、15、10倍量60~80%(体积比浓度)乙醇回流提取3次,提取时间分别为2、1.5、1.5小时,合并提取液,减压浓缩至浸膏,以1~2%稀酸水(盐酸、硫酸或硝酸等)酸化后,酸水液以氨水调PH值至9,氯仿萃取,减压回收氯仿所得稠膏,即为独行千里氯仿部位5.46g。Dried rhizomes of Lone Walking Thousand Miles were crushed, and 20, 15, and 10 times the amount of 60-80% (volume ratio concentration) ethanol was added to reflux extraction for 3 times, and the extraction time was 2, 1.5, and 1.5 hours respectively. The combined extracts were concentrated under reduced pressure to The extract is acidified with 1-2% dilute acid water (hydrochloric acid, sulfuric acid or nitric acid, etc.), the pH value of the acid water solution is adjusted to 9 with ammonia water, extracted with chloroform, and the thick paste obtained by recovering chloroform under reduced pressure is the chloroform part of Lone Walking Thousand Miles 5.46g.
将实施例1~5制备得到的氯仿部位进行碘化汞钾、碘化铋钾、硅钨酸生物碱指示剂的试管定性反应,均呈阳性反应。The chloroform parts prepared in Examples 1-5 were subjected to qualitative reactions in test tubes of mercuric potassium iodide, bismuth potassium iodide, and silicotungstic acid alkaloid indicators, all of which showed positive reactions.
实施例6涂抹剂制备Embodiment 6 smear preparation
称取聚乙烯醇120g(优选PVA05-88与17-88各60g),用10g甘油润湿后加入到300ml蒸熘水中浸泡溶涨。另取上述1~5任一实施例方法获得的独行千里有效部位(氯仿部位)50g与30g苯甲酸一起加入至500ml乙醇中在搅拌下至药物基本溶解或均匀混悬,搅拌均匀后缓缓加入聚乙烯醇液中,随加随搅拌,搅匀后过滤即得。Weigh 120g of polyvinyl alcohol (preferably 60g each of PVA05-88 and 17-88), wet it with 10g of glycerin and add it to 300ml of distilled water to soak and swell. In addition, take 50g of the effective fraction (chloroform fraction) obtained by the method of any one of the above 1~5 examples and add it together with 30g of benzoic acid into 500ml of ethanol and stir until the medicine is basically dissolved or uniformly suspended, and then slowly add In the polyvinyl alcohol liquid, stir as it is added, stir well and then filter.
实施例7软膏剂制备Embodiment 7 ointment preparation
称取硬脂酸100g在水浴上熔化,加入羊毛脂20g、白凡士林120g并水浴加热至80℃,另取上述1~5任一实施例方法获得独行千里有效部位50g加入;另将甘油120g及蒸镏水500ml加热至90℃,再加入十二烷基硫酸钠10g和羟苯乙酯1g溶解为水相,然后慢慢将水相倒入油相中,边加边搅拌直至冷凝,即得乳剂型软膏剂。Weigh 100g of stearic acid and melt it on a water bath, add 20g of lanolin, 120g of white vaseline and heat it to 80°C in a water bath, and add 50g of the effective part obtained by the method of any one of the above-mentioned 1 to 5 examples; add 120g of glycerin and Heat 500ml of distilled water to 90°C, then add 10g of sodium lauryl sulfate and 1g of ethylparaben to dissolve into the water phase, then slowly pour the water phase into the oil phase, and stir until it condenses to obtain Creamy ointment.
实施例8硬膏剂制备Embodiment 8 plaster preparation
取生胶洗净,切成适宜大小的条块,在炼胶机中塑炼成网状胶片,浸入适量的溶剂汽油中,浸泡至完全溶涨成凝胶状,移入打膏桶内搅拌3~4小时,依次加入凡士林、羊毛脂、松香、氧化锌等按照常规方法制成基质,再加入上述1~5任一实施例方法获得的独行千里有效部位5~50g,继续搅拌3小时,待已成均匀膏浆时,经涂布、切割、加衬、包装即得。Take the raw rubber, wash it, cut it into strips of appropriate size, masticate it into a mesh film in a rubber mixer, immerse it in an appropriate amount of solvent gasoline, soak it until it is completely swollen into a gel, and move it into a paste barrel and stir for 3 After ~4 hours, add vaseline, lanolin, rosin, zinc oxide, etc. in turn to make a matrix according to the conventional method, then add 5 ~ 50 g of the effective part of the lone thousand miles obtained by the method of any one of the above-mentioned 1 ~ 5 embodiments, continue to stir for 3 hours, wait for When it has become a uniform paste, it can be obtained after coating, cutting, lining and packaging.
实施例9凝胶剂制备Embodiment 9 gel preparation
取卡波姆980适量用10ml丙二醇润湿后,逐渐缓慢搅拌加入水90ml,使其充分溶涨;再加入10ml水溶解的1%苯甲酸钠溶液;上述1~5任一实施例方法获得的独行千里有效部位5~50g用丙二醇90ml研磨混悬,再加入至胶体中,搅拌均匀后,搅拌下滴加三乙醇胺,即制得凝胶剂。Take an appropriate amount of Carbomer 980 and wet it with 10ml of propylene glycol, gradually slowly stir and add 90ml of water to make it fully swell; then add 1% sodium benzoate solution dissolved in 10ml of water; Grind and suspend 5-50 g of the effective part of Qianli with 90 ml of propylene glycol, then add it to the colloid, stir evenly, and add triethanolamine dropwise under stirring to obtain a gel.
实施例10巴布剂制备Embodiment 10 cataplasm preparation
将1~20g的Ultrez 10(卡伯母,市购)撒在去离子水15ml中,低速搅拌30min,得到A相溶液;称取独行千里有效部位浸膏0.1~20g,加入少量水,加入10ml甘油、透皮促进剂,不断搅拌,水浴加热使熔化得B相;高岭土、二氧化钛混合均匀,再与聚丙烯酸钠NP700混合均匀,加入剩余甘油润湿,研匀,将熔化的稠膏加入,研匀;山梨醇、亚硫酸氢钠、EDTA用28ml去离子水溶解,逐渐缓慢加入到B相中;甘羟铝、柠檬酸溶解于18ml水中,为C相;搅拌中将C相透明溶液加入B相,再将A相加入B、C相的混合物中。研磨均匀后涂布在无纺布上,室温下放置过夜,干燥后,与保护层复合,切割成6×8cm2包装即可。1~20g of Sprinkle Ultrez 10 (Cabomu, commercially available) in 15ml of deionized water, stir at a low speed for 30min to obtain a phase A solution; weigh 0.1-20g of the extract from the effective part of Duxingqianli, add a small amount of water, add 10ml of glycerin, and a skin penetration enhancer , continuously stirred, heated in a water bath to melt to obtain phase B; kaolin, titanium dioxide mixed evenly, then mixed with sodium polyacrylate NP700 evenly, added the remaining glycerin to moisten, grinded evenly, added the melted thick paste, grinded evenly; Sodium bisulfate and EDTA were dissolved in 28ml of deionized water, and gradually added to phase B; aluminum glycolate and citric acid were dissolved in 18ml of water, which was phase C; while stirring, add the transparent solution of phase C to phase B, and then add phase A Add to phase B and C mixture. Grind it evenly and spread it on the non-woven fabric, leave it overnight at room temperature, after drying, compound it with the protective layer, cut it into 6×8cm 2 and pack it.
实施例11贴剂制备Embodiment 11 patch preparation
称取1~30g聚乙烯醇17-88,加入蒸馏水浸泡过夜,待其充分溶胀后,水浴回流至溶,备用。精密称取独行千里有效部位浸膏0.1~20g,加入无水乙醇10~30ml、甘油5~20ml、吐温800.1~1ml,适当加热溶解后趁热加入聚乙烯醇17-88胶液,缓慢搅拌混匀,涂布,干燥,即得。Weigh 1-30g of polyvinyl alcohol 17-88, add distilled water to soak overnight, after it is fully swollen, reflux in water bath until dissolved, and set aside. Precisely weigh 0.1-20g of the active part extract of Duxingqianli, add 10-30ml of absolute ethanol, 5-20ml of glycerin, and 800.1-1ml of Tween, heat and dissolve properly, add polyvinyl alcohol 17-88 glue while it is hot, and stir slowly Mix evenly, coat and dry, that is to say.
实施例12片剂Example 12 tablet
取上述1~5任一实施例方法获得的独行千里有效部位50g,粉碎后过80目筛,与淀粉120g、20g乳糖、羧甲基淀粉钠10g混匀,加8%淀粉桨适量制成软材,过20目筛制成湿颗粒,60℃干燥整粒后,加入干颗粒重量0.8%的硬脂酸镁为润滑剂,压制成1000素片,包薄膜衣即得。Take 50g of the effective part of Duxingqianli obtained by the method of any one of the above-mentioned 1 to 5, pass through an 80-mesh sieve after crushing, mix with 120g of starch, 20g of lactose, and 10g of sodium carboxymethyl starch, add 8% starch slurry in an appropriate amount to make soft Material, cross 20 mesh sieves to make wet granules, after drying at 60°C for granulation, add 0.8% magnesium stearate of dry granule weight as lubricant, press into 1000 plain tablets, and coat with film to get final product.
实施例13胶囊剂Embodiment 13 capsules
称取淀粉120g、糊精20g、羧甲基淀粉钠10g混匀后,逐渐缓慢加入药物(取上述1~5任一实施例方法获得的独行千里有效部位50g,加入95%乙醇适量,水浴融化成的液体),制成软材,过20目筛制成湿颗粒,60℃干燥整粒后,填充2号胶囊壳即可。After taking by weighing 120g of starch, 20g of dextrin, and 10g of sodium carboxymethyl starch, and mixing them evenly, slowly add the medicine (take 50g of the effective part of a thousand miles obtained by the method of any one of the above-mentioned 1 to 5 embodiments, add an appropriate amount of 95% ethanol, and melt in a water bath liquid), made into soft materials, passed through a 20-mesh sieve to make wet granules, dried at 60°C for granulation, and then filled with No. 2 capsule shells.
实施例14丸剂制备Embodiment 14 pill preparation
称取上述1~5任一实施例方法获得的独行千里有效部位50g,粉碎后过80目筛,适量蜂蜜作黏合剂泛制成丸。Weigh 50 g of the effective part of Duxingqianli obtained by the method of any one of the above 1 to 5 examples, crush it and pass it through an 80-mesh sieve, and use an appropriate amount of honey as a binder to form a pill.
实施例15颗粒剂制备Embodiment 15 Granule preparation
称取糖粉300g,乳糖50g、糊精150g混匀后,逐渐缓慢加入药物(取上述1~5任一实施例方法获得的独行千里有效部位5g,加入95%乙醇适量水浴融化成液体),制成软材,过14目筛制成湿颗粒,60℃干燥12目筛整粒后,分装(每袋重5g),包装即可。Weigh 300g of powdered sugar, 50g of lactose, and 150g of dextrin and mix well, then slowly add the drug (take 5g of the effective part of a thousand miles obtained by the method of any one of the above 1 to 5 embodiments, add 95% ethanol in an appropriate amount of water bath to melt into a liquid), Made into soft materials, passed through a 14-mesh sieve to make wet granules, dried at 60°C with a 12-mesh sieve for granulation, and packed separately (each bag weighs 5g), and then packed.
实施例16散剂制备Embodiment 16 powder preparation
取上述1~5任一实施例方法获得的独行千里有效部位5g,加入淀粉100g,混合均匀,分装每包1g,包装即得。Take 5g of the effective part of Duxingqianli obtained by the method of any one of the above-mentioned 1-5 examples, add 100g of starch, mix evenly, pack 1g per pack, and pack it.
实施例17乳剂制备Embodiment 17 emulsion preparation
将独行千里有效部位浸膏5~50g干燥后过120目筛的细粉,加入110ml豆油混合均匀,加入豆磷脂溶液(11g豆磷脂加入甘油18ml,再加水约50ml研磨用蒸馏水稀释至250ml),加蒸馏水至1000ml,用胶体磨匀化2次,即得。Dry 5-50g of the effective part extract of Duxingqianli and pass through a 120-mesh sieve into fine powder, add 110ml of soybean oil and mix evenly, add soy lecithin solution (add 11g of soy lecithin to 18ml of glycerin, add about 50ml of water, grind and dilute to 250ml with distilled water), Add distilled water to 1000ml, homogenize twice with a colloid mill, and obtain.
实施例18独行千里提取物的镇痛实验Example 18 The analgesic experiment of the extract of Lone Walking Thousand Miles
动物:ICR小鼠(由广州中医药大学动物中心提供),雌性,体重20.34±1.43g。Animals: ICR mice (provided by the Animal Center of Guangzhou University of Traditional Chinese Medicine), female, weighing 20.34±1.43g.
药品及试剂:独行千里有效部位(临用前以0.5%羧甲基纤维素(CMC)配成混悬液);阿司匹林片(石家庄制药有限公司,规格0.3g/片,临用时以0.5%CMC配成混悬液);0.5%CMC溶液。Drugs and reagents: effective parts of Duxingqianli (prepared with 0.5% carboxymethylcellulose (CMC) for suspension); aspirin tablets (Shijiazhuang Pharmaceutical Co., Ltd., specification 0.3g/tablet, with 0.5% CMC before use) Suspension); 0.5% CMC solution.
(1)扭体法:小鼠50只,适应性饲养三天,按体重随机分为5组,分别灌服独行千里氯仿部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、阿司匹林200mg/kg(阳性对照组)、0.5%CMC溶液(空白对照组),连续给药5天。实验前禁食16小时,自由饮水,灌胃给药后30min,腹腔注射0.6%冰醋酸溶液0.2ml,记录40min内小鼠扭体次数,进行组间t检验,结果见表1:(1) Twisting method: 50 mice were adaptively fed for three days, randomly divided into 5 groups according to body weight, and fed with chloroform parts (converted into medicinal materials) of 40g/kg (small dose group) and 80g/kg respectively. kg (medium dose group), 120g/kg (high dose group), aspirin 200mg/kg (positive control group), 0.5% CMC solution (blank control group), administered continuously for 5 days. Fasted for 16 hours before the experiment, free to drink water, 30 minutes after intragastric administration, 0.2ml of 0.6% glacial acetic acid solution was injected intraperitoneally, the number of writhing times of the mice within 40 minutes was recorded, and the t-test between groups was performed. The results are shown in Table 1:
表1独行千里有效部位对小鼠扭体次数的影响(x±SD,n=10)Table 1 The effect of effective fractions on the number of times of writhing in mice (x±SD, n=10)
注:与对照组比较,*P<0.01;△P<0.05Note: Compared with the control group, *P<0.01; △P<0.05
实验结果表明,与空白组比较,阿司匹林组、大剂量组均能显著减少小鼠扭体次数(P<0.01);大、中、小剂量组均可减少小鼠扭体次数(P<0.05)。The experimental results showed that, compared with the blank group, both the aspirin group and the high-dose group could significantly reduce the number of mice writhing (P<0.01); the large, medium and low-dose groups could all reduce the number of mice writhing (P<0.05) .
(2)热板法:小鼠50只(初筛痛阈在10~30s),适应性饲养三天,按体重随机分为5组,分别灌服独行千里氯仿部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、阿司匹林200mg/kg(阳性对照组)、0.5%CMC溶液(空白对照组),连续给药5天。末次给药40min后,再测痛阈。痛阈超过60s者以60s计算。服药后痛阈减去服药前痛阈即得服药后痛阈延长时间,结果见表2:(2) Hot plate method: 50 mice (primary screening pain threshold is 10-30s), adaptively fed for three days, randomly divided into 5 groups according to body weight, and fed with 40 g of chloroform parts (converted into medicinal materials) /kg (low-dose group), 80g/kg (middle-dose group), 120g/kg (high-dose group), aspirin 200mg/kg (positive control group), 0.5% CMC solution (blank control group), administered continuously for 5 sky. 40 minutes after the last administration, the pain threshold was measured again. Those whose pain threshold exceeds 60s are counted as 60s. The pain threshold after taking the medicine is subtracted from the pain threshold before taking the medicine to get the pain threshold extension time after taking the medicine. The results are shown in Table 2:
表2独行千里有效部位对小鼠痛域的影响(x±SD,n=10)Table 2 The effect of the effective parts of Lone Walking Thousand Miles on the pain domain of mice (x±SD, n=10)
注:与对照组比较,*P<0.01Note: Compared with the control group, *P<0.01
结果表明,与空白组比较,阿司匹林组、大剂量、中剂量组均能显著提高小鼠热板痛阈;小剂量组未能显著性提高小鼠的热板痛阈。镇痛实验结果表明,独行千里有效部位在大、中剂量下有明显的镇痛作用。The results showed that compared with the blank group, the aspirin group, high-dose, and medium-dose groups could significantly increase the hot-plate pain threshold of mice; the low-dose group could not significantly improve the hot-plate pain threshold of mice. The results of analgesic experiment show that the effective part of Duxingqianli has obvious analgesic effect at high and medium doses.
实施例19独行千里有效部位抗炎实验Example 19 Anti-inflammation experiment of the effective part of traveling thousands of miles alone
1、对抗二甲苯致小鼠耳廓肿胀所造成的炎症模型1. Anti-inflammatory model caused by xylene-induced ear swelling in mice
动物:ICR小鼠(由广州中医药大学动物中心提供)雌雄各半,体重20.31±1.66g。Animals: ICR mice (provided by the Animal Center of Guangzhou University of Traditional Chinese Medicine) are male and female, with a body weight of 20.31±1.66 g.
器材:小鼠灌胃器、BP-211D电子分析天平(北京赛多利斯天平有限公司)、50μL可调微量取样器、6mm打孔器Equipment: mouse gavage device, BP-211D electronic analytical balance (Beijing Sartorius Balance Co., Ltd.), 50μL adjustable micro sampler, 6mm hole punch
药品及试剂:独行千里有效部位(临用前以0.5%羧甲基纤维素(CMC)配成混悬液);阿司匹林片(石家庄制药有限公司,规格0.3g/片,临用时以0.5%CMC配成混悬液);0.5%CMC溶液。Drugs and reagents: effective parts of Duxingqianli (prepared with 0.5% carboxymethylcellulose (CMC) for suspension); aspirin tablets (Shijiazhuang Pharmaceutical Co., Ltd., specification 0.3g/tablet, with 0.5% CMC before use) Suspension); 0.5% CMC solution.
小鼠50只,适应性饲养三天,按体重随机分为5组,每组10只,灌服独行千里有效部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、阿司匹林200mg/kg(阳性对照组)、0.5%CMC溶液(空白对照组),每日一次,连续给药5天。末次给药1小时后,每只小鼠左耳两面均涂布二甲苯0.03ml致炎,30分钟后脱臼处死动物,沿耳廓基线剪下两耳,用6mm打孔器取双侧耳对称处的圆耳片,用电子分析天平称重,并计算肿胀度和抗炎抑制率。结果见表3。50 mice were adaptively fed for three days, randomly divided into 5 groups according to body weight, 10 in each group, and fed with the effective part (converted into medicinal material) 40g/kg (small dose group), 80g/kg (medium dose group) and 10 mice in each group. dose group), 120g/kg (high dose group), aspirin 200mg/kg (positive control group), 0.5% CMC solution (blank control group), once a day for 5 consecutive days. One hour after the last administration, each mouse was coated with 0.03ml of xylene on both sides of the left ear to cause inflammation. After 30 minutes, the animal was killed by dislocation. The round ears at the place were weighed with an electronic analytical balance, and the swelling degree and anti-inflammatory inhibition rate were calculated. The results are shown in Table 3.
肿胀度=左耳片重-右耳片重Swelling degree = left ear piece weight - right ear piece weight
抗炎抑制率(R)=(对照组平均肿胀度-给药组平均肿胀度)/对照组平均肿胀度×100%Anti-inflammatory inhibition rate (R)=(average swelling degree of control group-average swelling degree of administration group)/average swelling degree of control group×100%
表3独行千里有效部位对二甲苯所致小鼠耳壳肿胀的影响(x±SD,n=10)Table 3 The effect of the effective parts of Lone Traveling Thousand Miles on the ear swelling of mice caused by xylene (x±SD, n=10)
注:与对照组比较,*P<0.05,△P<0.01;与阿司匹林组相比,☆P<0.05Note: Compared with the control group, *P<0.05, △P<0.01; compared with the aspirin group, ☆P<0.05
从实验结果可知,独行千里有效部位大、中、小剂量组与对照组相比,均呈不同程度的抑制小鼠耳壳肿胀作用,具有随剂量增加而作用增强的趋势,大剂量组有极显著性差异(P<0.01),中、小剂量组有显著性差异(P<0.05)。与阿司匹林组比较,大剂量组有显著性差异(P<0.05),中、小剂量组均无显著性差异。From the experimental results, it can be seen that compared with the control group, the large, medium and small dose groups of the effective part of Lone Walking Thousand Miles all showed different degrees of inhibition of the swelling of the ear shells of mice, and the effect tended to increase with the increase of the dose. The high dose group had extremely There was a significant difference (P<0.01), and there was a significant difference between the medium and small dose groups (P<0.05). Compared with the aspirin group, there was a significant difference in the high-dose group (P<0.05), and there was no significant difference in the medium-dose and low-dose groups.
2、对蛋清致小鼠足趾肿胀的炎症模型2. Inflammation model of mouse toe swelling induced by egg white
小鼠50只,雌雄各半,随机分成5组,每组10只。灌服独行千里有效部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、阿司匹林200mg/kg(阳性对照组)、0.5%CMC溶液(空白对照组),每日一次,连续给药5天。末次给药1小时后,小鼠左后足掌皮内注入蛋清每只0.03ml,注射前及注射后1h、2h测定右后足容积。足爪肿胀增加百分率(%)=(致炎后右后足容积-致炎前右后足容积)/致炎前右后足容积×100%。实验结果见表4。Fifty mice, half male and half male, were randomly divided into 5 groups, 10 mice in each group. Feed the effective parts of Lone Walking Thousand Miles (converted into the amount of medicinal material) 40g/kg (low dose group), 80g/kg (medium dose group), 120g/kg (high dose group), aspirin 200mg/kg (positive control group), 0.5 % CMC solution (blank control group), administered once a day for 5 consecutive days. One hour after the last administration, 0.03 ml of egg white was intradermally injected into the left hind paw of the mice, and the volume of the right hind paw was measured before and 1 h and 2 h after the injection. Increased percentage of paw swelling (%)=(right hind paw volume after inflammation-right hind paw volume before inflammation)/right hind paw volume before inflammation×100%. The experimental results are shown in Table 4.
表4独行千里有效部位对蛋清所致小鼠足趾肿胀的影响(x±SD)Table 4 The effect of the effective parts of Lone Walking Thousand Miles on mouse toe swelling caused by egg white (x ± SD)
注:与对照组比较,△P<0.01;与阿司匹林组相比,☆P<0.01Note: Compared with the control group, △P<0.01; compared with the aspirin group, ☆P<0.01
实验结果表明,阿司匹林组、给药组与空白对照组相比,在2h均呈现了显著的抑制炎症肿胀的作用(P<0.01);大剂量组与阿司匹林组相比,也有显著性差异。The experimental results showed that compared with the blank control group, the aspirin group and the administration group all showed a significant effect of inhibiting inflammation and swelling at 2 hours (P<0.01); compared with the aspirin group, there was also a significant difference between the high-dose group and the aspirin group.
3、小鼠腹腔毛细管通透性实验3. Mouse peritoneal capillary permeability experiment
小鼠50只,雌雄各半,随机分成5组,每组10只。灌服独行千里有效部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、阿司匹林200mg/kg(阳性对照组)、0.5%CMC溶液(空白对照组),每日一次,连续给药5天。末次给药1小时后,取伊文思蓝生理盐水溶液,以0.1ml/10g尾静脉注射,立刻腹腔注射0.6%冰醋酸0.2ml/只。20分钟后,断脊椎处死,用剪刀剪开腹腔,以5ml生理盐水反复洗涤,将洗涤液以离心管收集,用离心机以1000r/min离心5分钟取滤液,滤液用UV2300型分光光度计,以590nm处波长测OD值,结果见表5。Fifty mice, half male and half male, were randomly divided into 5 groups, 10 mice in each group. Feed the effective parts of Lone Walking Thousand Miles (converted into the amount of medicinal material) 40g/kg (low dose group), 80g/kg (medium dose group), 120g/kg (high dose group), aspirin 200mg/kg (positive control group), 0.5 % CMC solution (blank control group), administered once a day for 5 consecutive days. One hour after the last administration, take Evans blue saline solution, inject it into the tail vein with 0.1ml/10g, and immediately inject 0.2ml of 0.6% glacial acetic acid intraperitoneally. After 20 minutes, the spine was cut off, the abdominal cavity was cut open with scissors, washed repeatedly with 5ml of normal saline, the washing liquid was collected in a centrifuge tube, centrifuged at 1000r/min for 5 minutes to take the filtrate, and the filtrate was measured with a UV2300 spectrophotometer. The OD value was measured at a wavelength of 590nm, and the results are shown in Table 5.
表5独行千里有效部位对小鼠毛细血管通透性的影响(x±SD)Table 5 The influence (x ± SD) of the effective fraction of the lone travel thousands of miles on the capillary permeability of mice
注:与对照组比较,△P<0.01Note: Compared with the control group, △P<0.01
实验结果表明,独行千里有效部位具有良好的抗炎作用。The experimental results show that the effective part of Lone Walking Thousand Miles has a good anti-inflammatory effect.
实施例20独行千里有效部位对大鼠佐剂性关节炎治疗作用Example 20 Therapeutic Effects of Effective Parts of Lonely Traveling Thousand Miles on Adjuvant Arthritis in Rats
本实验用弗氏完全佐剂(FAC)建立大鼠佐剂性关节炎(AA)模型,用游标卡尺测量大鼠足跖厚度,以FAC致炎后大鼠足跖肿胀度、病理改变程度为指标,观察独行千里有效部位的抗炎作用。In this experiment, a rat adjuvant arthritis (AA) model was established with Freund's complete adjuvant (FAC), and the thickness of the paws of the rats was measured with a vernier caliper. , to observe the anti-inflammatory effect of the effective part of Lonely Thousand Miles.
药物:独行千里有效部位、正清风痛宁片(西安利君集团)Drugs: effective parts of Duxingqianli, Zhengqing Fengtongning Tablets (Xi'an Lijun Group)
试剂:弗氏完全佐剂(Freund’s Adjuvant Complete,FAC)美国SIGMA公司产品。Reagent: Freund's Adjuvant Complete (FAC) product of SIGMA, USA.
动物:SD大鼠,雄性,体重180-200g。由广州中医药大学实验动物中心提供。Animals: SD rats, male, weighing 180-200 g. Provided by the Experimental Animal Center of Guangzhou University of Traditional Chinese Medicine.
仪器:A℃S-1EAS型电子天平(精度0.5g)北京市菲姆斯科技开发公司产品Instrument: A℃S-1EAS electronic balance (accuracy 0.5g) product of Beijing Feimusi Technology Development Co., Ltd.
大鼠50只,适应性饲养三天,按体重随机分为5组,分别灌服独行千里氯仿部位(折算成药材量)40g/kg(小剂量组)、80g/kg(中剂量组)、120g/kg(大剂量组)、正清风痛宁片组、模型组,连续给药2天后。第三天用游标卡尺在测量正常足厚度之后,每只大鼠右后足趾皮内注射弗氏完全佐剂0.1ml,并在6h、18h、24h、3d、5d分别测量致炎后足肿胀度,并在10d、14d、18d、22d、26d分别测定左后足趾(非致炎足)的厚度。50 rats were fed adaptively for three days, and were randomly divided into 5 groups according to their body weight. 120g/kg (high-dose group), Zhengqing Fengtongning Tablets group, model group, after continuous administration for 2 days. On the third day, after measuring the normal foot thickness with a vernier caliper, inject 0.1ml of Freund's complete adjuvant intradermally into the right hind toe of each rat, and measure the swelling degree of the inflammatory hind foot at 6h, 18h, 24h, 3d, and 5d respectively , and at 10d, 14d, 18d, 22d, and 26d, the thickness of the left hind toe (non-inflammatory foot) was measured respectively.
以足肿胀度为指标,采用SPSS13.0统计软件包进行单因素方差分析。急发性和继发性炎症实验结果分别见表6和表7。Taking the degree of paw swelling as an index, SPSS13.0 statistical software package was used for one-way analysis of variance. The results of acute and secondary inflammation experiments are shown in Table 6 and Table 7, respectively.
表6.独行千里有效部位对大鼠急性炎症实验结果(右足肿胀度)(x±SD,n=10)Table 6. Acute inflammation test results of effective parts of Lone Walking Thousand Miles on rats (right foot swelling) (x±SD, n=10)
注:与模型组相比:P>0.05*;P<0.01***;0.05>P>0.01**Note: Compared with the model group: P>0.05*; P<0.01***; 0.05>P>0.01**
从实验结果可知,24小时内为急性炎症的发生期,与模型组相比,给药组各个剂量和阳性对照组对其均有明显抗炎作用。24小时后为继发性炎症的形成期,各个给药组对继发性炎症形成虽有一定的抑制作用,但不是特别明显。3天后,给药组和阳性对照组的炎症抑制作用较弱。由此可见,独行千里有效部位高、中、低剂量组,对大鼠佐剂性关节炎急性炎症,均有抑制作用。From the experimental results, it can be known that acute inflammation occurs within 24 hours. Compared with the model group, each dose of the administration group and the positive control group have obvious anti-inflammatory effects on it. After 24 hours, it was the formation period of secondary inflammation. Although each administration group had a certain inhibitory effect on the formation of secondary inflammation, it was not particularly obvious. After 3 days, the anti-inflammatory effects of the administration group and the positive control group were weak. It can be seen that the high, medium and low dose groups of the effective part of Duxingqianli all have inhibitory effect on the acute inflammation of adjuvant arthritis in rats.
表7独行千里有效部位对大鼠继发性炎症实验结果(左足肿胀度)(x±SD,n=10)Table 7 The experimental results of the effective parts of Lonely Thousand Miles on secondary inflammation in rats (swelling degree of left foot) (x±SD, n=10)
注:与模型组相比:P<0.01***;0.05>P>0.01**Note: Compared with the model group: P<0.01***; 0.05>P>0.01**
从表7实验结果可知:18天以内是继发性炎症的形成期,药物对继发性炎症的形成有一定的抑制作用,作用相对缓和,无显著性。18天后,继发性炎症形成,药物的抗炎作用开始显效。与空白组相比,高、中剂量组和阳性对照组都有明显的抗炎作用。高剂量组26天有极显著性差异(P<0.01***),中剂量组与阳性对照组有显著性差异(P<0.05)。From the experimental results in Table 7, it can be seen that within 18 days is the formation period of secondary inflammation, and the drug has a certain inhibitory effect on the formation of secondary inflammation, and the effect is relatively mild and insignificant. After 18 days, secondary inflammation formed, and the anti-inflammatory effect of the drug began to be effective. Compared with the blank group, the high-dose and middle-dose groups and the positive control group all had obvious anti-inflammatory effects. There was an extremely significant difference (P<0.01***) in the high-dose group at 26 days, and a significant difference between the middle-dose group and the positive control group (P<0.05).
实施例21 独行千里有效部位对大鼠佐剂性关节炎病理改变的影响1组织固定和切片方法Example 21 Effect of the effective part of Duxingqianli on the pathological changes of adjuvant arthritis in rats 1 Tissue fixation and slicing methods
取材、固定和脱钙:取药效实验第26天结束,大鼠处死后,在踝关节上15mm处剪断后肢,用10%的中性福尔马林浸泡固定48h,再用甲酸脱钙液浸泡4周脱钙。Material collection, fixation and decalcification: after the 26th day of the drug efficacy experiment, the rats were killed, and the hind limbs were cut off at 15 mm above the ankle joint, soaked and fixed in 10% neutral formalin for 48 hours, and then decalcified with formic acid Soak for 4 weeks to decalcify.
冲洗:流水冲洗24h,洗去甲酸脱钙溶液。Rinse: Rinse with running water for 24 hours to remove the formic acid decalcification solution.
脱水:用系列浓度乙醇逐级脱水,70%乙醇30min,80%乙醇30min,90%乙醇30min,95%乙醇30min,无水乙醇I 60min,无水乙醇II30min。Dehydration: dehydration with series concentration of ethanol step by step, 70% ethanol for 30min, 80% ethanol for 30min, 90% ethanol for 30min, 95% ethanol for 30min, absolute ethanol I for 60min, absolute ethanol II for 30min.
透明:二甲苯I 20min,二甲苯II观察至组织透明。Transparent: xylene I 20min, xylene II observation until the tissue is transparent.
浸蜡:透明后的组织立即置于预先用烤箱融化的石蜡中,石蜡I60min,石蜡II 60min。Wax immersion: The transparent tissue was immediately placed in paraffin wax melted in an oven in advance, paraffin wax I 60min, paraffin wax II 60min.
包埋:将组织定向置于装有融化石蜡的包埋板中,待石蜡凝固成块。Embedding: Place the tissue in an embedding plate filled with melted paraffin, and wait for the paraffin to solidify into a block.
切片、贴片和烤片:用石蜡切片机将蜡块切成6μm的薄片,将蜡片贴在涂有蛋白甘油的载玻片上,45℃恒温箱内过夜后,常温下保存待染色。Slicing, patching and baking: Cut the wax block into 6 μm thin slices with a paraffin microtome, stick the wax slice on a glass slide coated with protein glycerin, and store it at room temperature for staining after overnight in an incubator at 45°C.
2HE染色步骤2HE staining steps
将烤干的切片放入二甲苯I、二甲苯II、二甲苯III各5min脱蜡;依次移入无水乙醇I、无水乙醇II、95%乙醇、90%乙醇、80%乙醇、70%乙醇、60%乙醇、50%乙醇、蒸馏水中复水,各5min;苏木精染色5min;自来水洗、蒸馏水洗各3遍;1%盐酸乙醇分色5秒钟;自来水洗3遍,氨水碱化10秒;蒸馏水洗3遍;0.5%伊红酒精染色13min;依次移入90%乙醇、95%乙醇、无水乙醇I各0.5min;无水乙醇II 5min;二甲苯I、二甲苯II、二甲苯III各5min;最后用中性树胶封片。Put the dried slices into xylene I, xylene II, and xylene III for 5 minutes each to dewax; transfer them into absolute ethanol I, absolute ethanol II, 95% ethanol, 90% ethanol, 80% ethanol, and 70% ethanol in sequence , 60% ethanol, 50% ethanol, and rehydration in distilled water, each for 5 minutes; hematoxylin staining for 5 minutes; tap water and distilled water for 3 times; 1% hydrochloric acid ethanol color separation for 5 seconds; tap water for 3 times, ammonia alkalization 10 seconds; wash 3 times with distilled water; stain with 0.5% eosin alcohol for 13 minutes; transfer into 90% ethanol, 95% ethanol, absolute ethanol I for 0.5 minutes each; absolute alcohol II for 5 minutes; xylene I, xylene II, xylene III each for 5 minutes; finally seal the slide with neutral gum.
实验结果:Experimental results:
致炎后第26天的AA大鼠踝关节组织切片显微镜下观察,模型组可见滑膜内炎性细胞浸润,滑膜组织肿胀,有少量纤维组织渗出;滑膜细胞有一定程度增生,排列不规则;滑膜层下毛细血管扩张,血管腔内充满炎性细胞。见附图1所示。On the 26th day after inflammation, AA rat ankle tissue slices were observed under a microscope. In the model group, inflammatory cell infiltration in the synovium was seen, the synovial tissue was swollen, and a small amount of fibrous tissue exuded; the synovial cells proliferated to a certain extent, arranged Irregular; subsynovial telangiectasia, vascular lumen filled with inflammatory cells. See attached drawing 1.
各给药组镜下所见,滑膜组织炎性细胞较少,滑膜肿胀较轻纤维组织渗出不明显;滑膜细胞有增生但程度低于模型组;滑膜层毛细血管腔内炎性细胞较少,见附图2~4所示,阳性对照组结果见附图5。Microscopically, the synovial tissue showed less inflammatory cells, less swollen synovial tissue and no obvious exudation of fibrous tissue in each administration group; synovial cell hyperplasia but lower than that in the model group; synovial capillary endoluminal inflammation There were few sex cells, as shown in accompanying drawings 2 to 4, and the results of the positive control group were shown in accompanying drawing 5.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010122485 CN101780124B (en) | 2010-03-12 | 2010-03-12 | A kind of Lonely Thousand Miles Extract and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010122485 CN101780124B (en) | 2010-03-12 | 2010-03-12 | A kind of Lonely Thousand Miles Extract and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101780124A true CN101780124A (en) | 2010-07-21 |
CN101780124B CN101780124B (en) | 2013-01-30 |
Family
ID=42520348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010122485 Expired - Fee Related CN101780124B (en) | 2010-03-12 | 2010-03-12 | A kind of Lonely Thousand Miles Extract and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101780124B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860734A (en) * | 2014-03-14 | 2014-06-18 | 于蔚蔚 | Traditional Chinese medicine fuming and washing agent for treating ankylosis after wrist fracture and nursing method |
CN105434529A (en) * | 2015-12-18 | 2016-03-30 | 武汉市第一医院 | Radix scutellariae-rhizoma atractylodis macrocephalae cataplasm used for treating primary dysmenorrheal, and preparation method thereof |
CN110384721A (en) * | 2019-08-28 | 2019-10-29 | 广东药科大学 | A kind of extracting method of the anti-inflammatory active component of acuteleaf caper root |
-
2010
- 2010-03-12 CN CN 201010122485 patent/CN101780124B/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
《广东医药学院学报》 19900630 陈熔,等 独行千里化学成分研究 第12-13页 权利要求1-5 第6卷, 第1期 * |
《海峡药学》 20070731 童家赟,等 独行千里的生药鉴别 第65-66页 权利要求1-10 第19卷, 第7期 * |
童家赟,等: "独行千里的生药鉴别", 《海峡药学》 * |
陈熔,等: "独行千里化学成分研究", 《广东医药学院学报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860734A (en) * | 2014-03-14 | 2014-06-18 | 于蔚蔚 | Traditional Chinese medicine fuming and washing agent for treating ankylosis after wrist fracture and nursing method |
CN103860734B (en) * | 2014-03-14 | 2016-02-17 | 于蔚蔚 | A kind ofly treat the stiff Chinese medicine fuming-lotion of Wrist fracture posterior joint and care method |
CN105434529A (en) * | 2015-12-18 | 2016-03-30 | 武汉市第一医院 | Radix scutellariae-rhizoma atractylodis macrocephalae cataplasm used for treating primary dysmenorrheal, and preparation method thereof |
CN110384721A (en) * | 2019-08-28 | 2019-10-29 | 广东药科大学 | A kind of extracting method of the anti-inflammatory active component of acuteleaf caper root |
CN110384721B (en) * | 2019-08-28 | 2021-11-23 | 广东药科大学 | Method for extracting anti-inflammatory effective part of striga asiatica |
Also Published As
Publication number | Publication date |
---|---|
CN101780124B (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102319275B (en) | Sunset abelmoschus flower extract, preparation and preparation method thereof | |
CN102600219A (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
WO2018058261A1 (en) | Traditional chinese medicine composition for treating psoriasis and preparation method thereof | |
CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
WO2019072051A1 (en) | Traditional chinese medicine extract with anti-depressive effect and preparation method and application thereof | |
CN105687441A (en) | Application of litchi rind polyphenol in medicines for treating hyperglycemia and insulin resistance | |
CN101450092B (en) | Vladimiria root extract, composition containing the vladimiria root extract and use thereof | |
CN101780124B (en) | A kind of Lonely Thousand Miles Extract and its preparation method and application | |
CN103405494B (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
CN109575102A (en) | The application of trilliaceae total steroidal saponin and wherein steroid saponin compound in preparation treatment ulcerative colitis drug | |
CN102302615B (en) | Effective site group of daphne giraldii nitsche leaf, preparation method, medicinal composition and application thereof | |
CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
CN102697932B (en) | Medicinal composition for treating skin itch and quality detection method | |
CN101554406A (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
CN101147767B (en) | Preparation method of medicinal composition for treating acne | |
CN104435293B (en) | Application of ethanolic extract of total triterpenes of Schisandra chinensis in the preparation of anti-arthritis drugs | |
CN103372159A (en) | Semen-coicis extract with function of reducing blood uric acid and method for preparing same | |
CN102258587B (en) | Preparation method and application of red paeony root active ingredient | |
CN107126450B (en) | A Chinese medicinal preparation containing extract and effective substance, and its preparation method and application | |
CN103417644B (en) | A kind of Heiguteng exract compound extract and its production and use | |
CN102631418B (en) | Antiphlogistic and analgesic traditional Chinese medicine extract and preparation method thereof | |
CN108578541A (en) | A kind of Chinese medical extract that treating rheumatism and cardiovascular and cerebrovascular disease, preparation method and applications | |
CN102512496B (en) | A kind of total phenanthrenonequinone extract of salvia miltiorrhiza for treating vasculitis, pharmaceutical composition and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130130 |